UK-based investment research firm Edison updated its views on GW Pharma (NASDAQ: GWPH) today. Analyst Maxim Jacobs is targeting a price of 587 pence, which, at the current dollar/pound conversion of 1.40, approximates $87 for the U.S. ADS. GWPH closed near $43 on 02/24. The summary provided on the report:
With four Phase III trials of Epidiolex (cannabidiol or CBD) in various forms of pediatric epilepsy, two for Dravet syndrome and two for Lennox-Gastaut syndrome (LGS) expected to provide top-line readouts in 2016 (with three in H116), investors are understandably laser-focused on these programmes. Based on an analysis of the previous results of other molecules in Dravet and LGS, as well as data from the expanded access programme, we are confident that the trials are sufficiently powered to demonstrate a statistically significant benefit for those patients taking Epidiolex.
The 12-page report provides a business summary, a discussion of valuation, a review of the financials, and some additional information about management and major shareholders.
Read the full report: http://www.edisoninvestmentresearch.com/research/report/gw-pharmaceuticals43/full
